Ziad Rouag is an Operational Executive and Entrepreneur in the Medical Device Industry advising leading incubators and start-ups. Ziad is an advisor to several medical start-ups and resides in San Francisco and Paris.
Prior to establishing ORAN consulting and joining Biomodex as President and CEO, Ziad served as Head of Toxicology, Pharmacokinetics, Regulatory, Clinical, Data Management and Statistics at JUUL Labs a venture funded start-up that developed a breakthrough nicotine delivery system (Altria acquisition). Previously, Ziad served as Vice President, Pre-clinical, Regulatory and Clinical Affairs for PQ Bypass (Fogardy Institute for Innovation incubation), a venture funded start-up that developed a breakthrough endovascular arterial venous bypass system, spearheading a highly successful clinical trials and EU launch and setting the ground for a US IDE. Ziad further served as Vice President, Pre-clinical, Regulatory, Quality and Clinical Affairs for Altura Medical (Lombard Medical acquisition), a venture funded start-up that developed a modular endograft for treating complex abdominal aortic aneurysm. Prior to that, Ziad held several senior positions including Vice President, Regulatory, Quality and Clinical Affairs at Auxogyn (Stanford Byers Center for Biodesign incubation - Progyny Merger) and Avinger (IPO (AVGR) NASDAQ).
Further positions included, Director positions with Johnson and Johnson (Codman) and Evalve (Foundry Group incubation - Abbott acquisition). Previously Ziad held several Regulatory and Legal positions with Guidant (Abbott acquisition), Novartis and a MedDevice Plaintiff Legal Committee, focusing on medical device class action litigation.
Ziad is fluent in several languages, has lived in several countries and holds B.S. and B.A degrees in Biology and Economics and a Juris Doctorate Degree. Ziad is admitted to practice law in the United States.